learn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
Search
for
Did you mean Kintor Pharmaceuticals?
Learn
5 / 801 resultslearn Kopexil
learn Kumquat fruit extract
learn Hinokitiol
learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
Research
5 / 402 results
research Colchicine in Managing Skin Conditions: A Systematic Review
Colchicine might help treat different skin diseases, but more research is needed to confirm its effectiveness and safe dosage.
research Technological Advances in Anti-hair Loss and Hair Regrowth Cosmeceuticals: Mechanistic Breakthroughs and Industrial Prospects Driven by Multidisciplinary Collaborative Innovation
Collaboration and innovation are key to developing effective, safe hair loss treatments.
research Hair growth and rejuvenation: An overview
The document concludes that minoxidil and finasteride are proven for hair growth, herbal remedies show promise, but more research is needed to confirm their effectiveness.
research A decade of progress in androgenetic alopecia management: Emerging therapies and multimodal strategies
Androgenetic alopecia treatments are becoming more personalized and include new therapies like topical antiandrogens and regenerative strategies.
research Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?
Investing in a longevity megafund can help pension funds reduce longevity risk.
Community Join
5 / 403 resultscommunity Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US_Kintor Pharmaceutical Limited
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
community New Hair Loss Treatment from Kintor Just Hit the Market: KX-826!
Kintor Pharmaceutical's new hair loss treatment, KX-826, is entering the market. Users are eager to see its effectiveness before celebrating.
community PP405 Update and My Take on Pelage
Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.
community I interviewed Kintor: GT20029 Clinical Trial Pictures. As well as KX826.
GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.
community Reminder that Kintors Pyrilutamide results will be out this month
Kintor's Pyrilutamide results for hair loss treatment will be released soon. The treatment may replace current treatments like finasteride and minoxidil without systemic side effects.